Specialty Pharmacy

MS-related inflammation may affect fertility.

The FDA is considering expanding the use for a drug currently indicated as a chronic hepatitis C (HCV) treatment.

Health information sharing web site helps connect patients among more than 2500 conditions.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the growth of the annual NASP Specialty Pharmacy Conference, held from Sept. 29 through Oct. 1, 2015.

Tecfidera reduces annualized MS relapse rate by 63% compared with placebo.

Vaginal rings show promise for administering medication and preventing the spread of sexual transmitted infections.

Study findings may change the development of cancer therapy.

Varying prevalence of fatigue from RA has been reported due to differences in definitions and measures.

FOXC1 gene is needed to turn cells into specialized tissues such as the eyes, kidney, brain, and bone.

The FDA's Office of Generic Drugs (OGD) will no longer require final printed labeling to approve Abbreviated New Drug Applications (ANDAs).

The FDA has approved a new treatment combination of Gilead's ambrisentan (Letairis) with tadalafil to treat pulmonary arterial hypertension.

Medical Marijuana Advocates Group helps patients access care through programs that lower the cost of seeing a physician.

Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses the difficulties pharmacies face regarding clinical support for patients starting specialty therapies.

Study finds that drop in support for health care spending is attributable to the Affordable Care Act, not the recession.

Study examines the potential impact from GLP-1 agonists, or incretin mimetics to treat diabetes.

Researchers examine the correlation between vitamin D levels and MS risk in African Americans or Hispanics.

Ex-vivo lung perfusion keeps the lung alive, breathing outside the body and supported by a supply of blood and nutrients.

Shortened telomere length may help inhibit cancer, but it is also associated with the progression of aging in humans.

Agreement represents the largest regional trade accord in history, which could have wide ranging impact on health care.

Roche has launched a new HbA1C test to identify diabetes risk and diagnose and monitor patients with diabetes.

Inhibiting the protein PARP 14 shows promise in stopping uncontrolled cancer cell growth.

Joseph Morse, president and chief operating officer of Therigy, LLC, discusses significant challenges in over the next five years in specialty pharmacy.

Research may lead to targeted therapies with reduced side effects.

Cladribine was previously denied market authorization on the suspicion that it may cause cancer.

Patients should be closely monitored by proper diagnostic methods.

The FDA has accepted Sandoz's Biologics License Application (BLA) for its proposed etanercept (Enbrel) biosimilar.

Study finds inhibition of the NOTCH4 signal may be a promising target to prevent the growth and spread of cancer.

Novel method may reduce the length of treatment time and decrease side effects.